176 related articles for article (PubMed ID: 24691419)
1. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.
Fox R; Berhane S; Teng M; Cox T; Tada T; Toyoda H; Kumada T; Kagebayashi C; Satomura S; Johnson PJ
Br J Cancer; 2014 Apr; 110(8):2090-8. PubMed ID: 24691419
[TBL] [Abstract][Full Text] [Related]
2. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
3. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
Wongjarupong N; Negron-Ocasio GM; Chaiteerakij R; Addissie BD; Mohamed EA; Mara KC; Harmsen WS; Theobald JP; Peters BE; Balsanek JG; Ward MM; Giama NH; Venkatesh SK; Harnois DM; Charlton MR; Yamada H; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
World J Gastroenterol; 2018 Mar; 24(12):1321-1331. PubMed ID: 29599607
[TBL] [Abstract][Full Text] [Related]
4. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers.
Toyoda H; Kumada T; Osaki Y; Oka H; Urano F; Kudo M; Matsunaga T
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1528-36. PubMed ID: 17162244
[TBL] [Abstract][Full Text] [Related]
5. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.
Toyoda H; Tada T; Johnson PJ; Izumi N; Kadoya M; Kaneko S; Kokudo N; Ku Y; Kubo S; Kumada T; Matsuyama Y; Nakashima O; Sakamoto M; Takayama T; Kudo M;
J Gastroenterol; 2017 Oct; 52(10):1112-1121. PubMed ID: 28224228
[TBL] [Abstract][Full Text] [Related]
6. The Predictive Power of Serum α-Fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma.
Tsugawa D; Fukumoto T; Kido M; Takebe A; Tanaka M; Kuramitsu K; Matsumoto I; Ajiki T; Koyama T; Ku Y
Kobe J Med Sci; 2015 Mar; 61(5):E124-31. PubMed ID: 27363395
[TBL] [Abstract][Full Text] [Related]
7. BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study.
Wongjarupong N; Negron-Ocasio GM; Mara KC; Prasai K; Abdallah MA; Ahn KS; Yang JD; Addissie BD; Giama NH; Harmsen WS; Therneau TM; Roberts LR
HPB (Oxford); 2021 May; 23(5):762-769. PubMed ID: 33023823
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
10. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
Arai T; Kobayashi A; Ohya A; Takahashi M; Yokoyama T; Shimizu A; Motoyama H; Furusawa N; Notake T; Kitagawa N; Sakai H; Imamura H; Kadoya M; Miyagawa S
Int J Clin Oncol; 2014 Oct; 19(5):871-9. PubMed ID: 24218280
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
12. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.
Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M
Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
15. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
16. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Berhane S; Toyoda H; Tada T; Kumada T; Kagebayashi C; Satomura S; Schweitzer N; Vogel A; Manns MP; Benckert J; Berg T; Ebker M; Best J; Dechêne A; Gerken G; Schlaak JF; Weinmann A; Wörns MA; Galle P; Yeo W; Mo F; Chan SL; Reeves H; Cox T; Johnson P
Clin Gastroenterol Hepatol; 2016 Jun; 14(6):875-886.e6. PubMed ID: 26775025
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States.
Carr BI; Kanke F; Wise M; Satomura S
Dig Dis Sci; 2007 Mar; 52(3):776-82. PubMed ID: 17253135
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):111-7. PubMed ID: 16431313
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
